Dilated Cardiomyopathy is an indication for drug development with over 30 pipeline drugs currently active. According to GlobalData, preregistered drugs for Dilated Cardiomyopathy have a 100% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Dilated Cardiomyopathy compared to historical benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Dilated Cardiomyopathy overview
Dilated cardiomyopathy (DCM) is a condition in which the heart’s ability to pump blood is decreased because the heart’s main pumping chamber, the left ventricle, is enlarged and weakened. Symptoms include fatigue and weakness, shortness of breath (dyspnea), lightheadedness, dizziness or fainting, persistent cough or wheezing, lack of appetite, sudden weight gain from fluid retention, and swelling (edema) in legs, ankles, and feet. Risk factors include family history, alcoholism, hypertension, cocaine abuse, and metabolic disorders, such as thyroid disease or diabetes.
For a complete picture of PTSR and LoA scores for drugs in Dilated Cardiomyopathy, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.